Safety review of 20-valent pneumococcal conjugate vaccine

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2039卷 / 1期
关键词：
D O I：
10.1007/s40278-024-72446-0
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 9
相关论文
共 50 条
  • [21] Cost-effectiveness of the 20-valent pneumococcal conjugate vaccine versus the 23-valent pneumococcal polysaccharide vaccine for older adults in South Korea
    Kang, Dong-Won
    Kim, Chae-Rin
    Song, Joon Young
    Park, Sun-Kyeong
    VACCINE, 2024, 42 (04) : 871 - 878
  • [22] Budgetary Impact of 20-Valent Pneumococcal Conjugate Vaccine Use for Adult Expatriates Living in Dubai
    Zayed, Mostafa
    Joury, Jean
    Farghaly, Mohamed
    Al Dallal, Sara
    Mahboub, Bassam
    Kutrieb, Emily
    Averin, Ahuva
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2023, 98
  • [23] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Malene, B. Mikkelsen
    Oyvind, Husby
    Tor, Molden
    David, N. Mwaura
    Jens, Olsen
    Nanna, V. Kristensen
    Jeffrey, Vietri
    COST EFFECTIVENESS AND RESOURCE ALLOCATION, 2023, 21 (01)
  • [24] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian setting
    Mikkelsen Malene B
    Husby Oyvind
    Molden Tor
    Mwaura David N
    Olsen Jens
    Kristensen Nanna V
    Vietri Jeffrey
    Cost Effectiveness and Resource Allocation, 21
  • [25] A trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in populations of adults ≥ 65 years of age with different prior pneumococcal vaccination
    Cannon, Kevin
    Elder, Charles
    Young, Mariano
    Scott, Daniel A.
    Scully, Ingrid L.
    Baugher, Gary
    Peng, Yahong
    Jansen, Kathrin U.
    Gruber, William C.
    Watson, Wendy
    VACCINE, 2021, 39 (51) : 7494 - 7502
  • [26] Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme
    Esra Çakar
    An Ta
    Michel Peters
    Elizabeth Vinand
    Angela Waterval-Overbeek
    Aleksandar Ilic
    Johnna Perdrizet
    Infectious Diseases and Therapy, 2025, 14 (3) : 527 - 547
  • [27] A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants
    Senders, Shelly
    Klein, Nicola P.
    Tamimi, Noor
    Thompson, Allison
    Baugher, Gary
    Trammel, James
    Peng, Yahong
    Giardina, Peter
    Scully, Ingrid L.
    Pride, Michael
    Center, Kimberly J.
    Gruber, William C.
    Scott, Daniel A.
    Watson, Wendy
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2024, 43 (06) : 596 - 603
  • [28] PROVISIONAL RESULTS ON THE INCIDENCE OF PNEUMONIA AND INVASIVE PNEUMOCOCCAL DISEASE IN RISK PATIENTS VACCINATED WITH THE 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
    Perez Muto, V.
    Baron Miras, L. E.
    Mena Pinilla, G.
    Aldea Novo, M.
    Vilella I Morato, A.
    GACETA SANITARIA, 2023, 37 : S254 - S255
  • [29] Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in Denmark compared with PPV23
    Olsen, Jens
    Schnack, Henrik
    Skovdal, Mette
    Vietri, Jeffrey
    Mikkelsen, Malene Buch
    Poulsen, Peter Bo
    JOURNAL OF MEDICAL ECONOMICS, 2022, 25 (01) : 1240 - 1254
  • [30] Potential impact of replacing the 13-valent pneumococcal conjugate vaccine with 15-valent or 20-valent pneumococcal conjugate vaccine in the 1+1 infant schedule in England: a modelling study
    Choi, Yoon Hong
    Bertran, Marta
    Litt, David J.
    Ladhani, Shamez N.
    Miller, Elizabeth
    LANCET PUBLIC HEALTH, 2024, 9 (09):
12345